Incyte (Nasdaq: INCY) announced the issuance of restricted stock unit (RSU) awards totaling 9,502 shares to 14 new employees under its 2024 Inducement Stock Incentive Plan. The RSUs vest 25% annually over four years, contingent on continued employment. This move aligns with Nasdaq Listing Rule 5635(c)(4) to attract top talent.
SPIE, the International Society for Optics and Photonics, has inducted 47 new Distinguished Fellows in 2025, recognizing their outstanding achievements in optics, photonics, and medical imaging. Since its founding in 1955, over 1,800 members have been honored with this distinction.
Franklin Resources, Inc. [NYSE: BEN] will release its Q1 2025 operating results on January 31, 2025, at 8:30 a.m. Eastern Time, followed by a live teleconference at 11:00 a.m. led by key executives, including CEO Jenny Johnson. Access to the teleconference and replay will be available via their investor portal or through designated phone lines. Franklin Resources, operating as Franklin Templeton, is a global investment management firm serving clients in over 150 countries with over $1.6 trillion in assets under management as of November 30, 2024.
SPIE, the international society for optics and photonics, has announced 47 new members to its prestigious Fellows program for 2025. The honorees, from academia, industry, and government, are recognized for their technical achievements and contributions to the optics and photonics fields. This year’s distinguished Fellows include leaders like Jeremy Voss (Michigan Technological University), Sona Hosseini (Jet Propulsion Laboratory), and Jess Wade (Imperial College London). The Fellows will be celebrated at upcoming SPIE symposiums. SPIE, founded in 1955, has supported the optics community with over $25 million in resources and initiatives in the past five years.
The Law Offices of Frank R. Cruz is investigating BioAge Labs, Inc. (NASDAQ: BIOA) for potential federal securities law violations. After its September 2024 IPO at $18 per share, BioAge’s stock price plummeted 76.85% to $4.65 following the December 6, 2024 announcement of discontinuing its STRIDES Phase 2 trial due to safety concerns. Investors who incurred losses are encouraged to contact the firm for potential claims.
Copyright © Todas las marcas son propiedad de la respectiva empresa o de BORGES MEDIA INC. Queda prohibida la reproducción total o parcial de cualquiera de los contenidos que aquí aparecen, así como su traducción a cualquier idioma sin autorización escrita de su propietario, la mejor revista de Sacramento. Consulte nuestra Política de Privacidad.
